{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:12:02Z","timestamp":1784715122303,"version":"3.55.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Cognitive impairment is a principal manifestation of Alzheimer disease (AD). To provide a clinical reference for the treatment of AD, a network meta-analysis (NMA) was performed to evaluate the effects of different anti-dementia drugs on the cognitive impairment exhibited by patients with AD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Relevant randomized controlled trials are found through the Pubmed database, Web of Science, Clinical Trials, Embase, Cohranne library, Chinese National Knowledge Infrastructure database, CBM databases, and Wanfang among others. A total of 33 articles were collected, with the earliest document collected having been published in February 2017. The included reports were screened for quality of papers by using strict inclusion and exclusion criteria. All analyses were based on previously published studies reporting de-identified data; thus, no ethical approval or patient consent were required. The Mini-Mental State Examination scores informed the classification of the 33 articles into a mild subgroup, which featured 11 articles, and 12 drugs (besides a placebo); a moderate subgroup, which featured 17 articles and 15 drugs (besides a placebo); and a severe subgroup, which featured 5 articles and 3 drugs (besides a placebo).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>While donepezil, galanthamine, and huperzine demonstrated the highest efficacy in the mild cognitive dysfunction subgroup (mean difference\u200a=\u200a5.2, 2.5, and 2.4, respectively). Donepezil, huperzine A, and rivastigmine achieved the most significant effects in the moderate cognitive dysfunction subgroup (MD\u200a=\u200a3.8, 2.9, and 3.0 respectively). In the severe subgroup, donepezil was demonstrably superior to memantine. Donepezil was thus found to effectively address cognitive impairment in patients with AD regardless of the degrees of cognitive decline.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Evaluation of the clinically common anti-dementia drugs using NMA affirmed the utility of cholinesterase inhibitors, especially donepezil, in alleviating cognitive dysfunction of patients with AD. This study may therefore help to inform the clinical selection of pharmacotherapeutic interventions addressing cognitive dysfunction in patients with AD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000016091","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T20:45:13Z","timestamp":1562791513000},"page":"e16091","source":"Crossref","is-referenced-by-count":22,"title":["The effect of anti-dementia drugs on Alzheimer disease-induced cognitive impairment"],"prefix":"10.1097","volume":"98","author":[{"given":"Cui-Cui","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","article-title":"Network meta-analysis for indirect treatment comparisons","volume":"21","author":"Lumley","year":"2010","journal-title":"Stat Med"},{"key":"R2-20230914","first-page":"941","article-title":"Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial","volume":"82","author":"Zhang","year":"2002","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2165\/11310960-000000000-00000","article-title":"Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study","volume":"24","author":"Santoro","year":"2010","journal-title":"CNS Drugs"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2174\/156720510791383831","article-title":"Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease","volume":"7","author":"Maher-Edwards","year":"2010","journal-title":"Curr Alzheimer Res"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4088\/JCP.08m04606","article-title":"Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study","volume":"70","author":"Hampel","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archneur.63.1.49","article-title":"A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease","volume":"63","author":"Reisberg","year":"2006","journal-title":"Arch Neurol"},{"key":"R7-20230914","first-page":"947","article-title":"Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial","volume":"9","author":"Wade","year":"2014","journal-title":"Clin Interv Aging"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/JGP.0b013e3181557b47","article-title":"Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses","volume":"15","author":"Mintzer","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/00023210-200620040-00005","article-title":"Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease","volume":"20","author":"Johannsen","year":"2006","journal-title":"CNS Drugs"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jama.283.8.1007","article-title":"Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study","volume":"283","author":"Mulnard","year":"2000","journal-title":"JAMA"},{"key":"R11-20230914","first-page":"391","article-title":"Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease","volume":"16","author":"Xu","year":"1995","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00406-011-0234-2","article-title":"Longitudinal changes of fractional anisotropy in Alzheimer's disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study","volume":"262","author":"Likitjaroen","year":"2012","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R14-20230914","first-page":"486","article-title":"Huperzine-A in capsules and tablets for treating patients with Alzheimer disease","volume":"20","author":"Xu","year":"1999","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1212\/WNL.57.8.1515","article-title":"Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease","volume":"57","author":"Adair","year":"2001","journal-title":"Neurology"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1212\/01.WNL.0000096376.03678.C1","article-title":"Idebenone treatment fails to slow cognitive decline in Alzheimer's disease","volume":"61","author":"Thal","year":"2003","journal-title":"Neurology"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa050151","article-title":"Vitamin E and donepezil for the treatment of mild cognitive impairment","volume":"352","author":"Petersen","year":"2005","journal-title":"N Engl J Med"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(06)68350-5","article-title":"Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study","volume":"367","author":"Winblad","year":"2006","journal-title":"Lancet"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1212\/01.wnl.0000266627.96040.5a","article-title":"Donepezil preserves cognition and global function in patients with severe Alzheimer disease","volume":"69","author":"Black","year":"2007","journal-title":"Neurology"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/gps.1856","article-title":"A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease","volume":"23","author":"Connelly","year":"2008","journal-title":"Int J Geriatr Psychiatry"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","article-title":"Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study","volume":"372","author":"Doody","year":"2008","journal-title":"Lancet"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2013.282834","article-title":"Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial","volume":"311","author":"Dysken","year":"2014","journal-title":"JAMA"},{"key":"R23-20230914","first-page":"25","article-title":"The rapeutic effect of simvastatin on cognitive dysfunction in patients with vascular dementia: a report of 49 cases","volume":"41","author":"Yong","year":"2010","journal-title":"J New Medicine"},{"key":"R24-20230914","first-page":"48","article-title":"Clinical observation of fluvastatin in the treatment of mild to moderate Alzheimer's disease","author":"Huang","year":"2010","journal-title":"Pract Geriatr"},{"key":"R25-20230914","first-page":"476","article-title":"Efficacy and safety of atorvastatin calcium in the treatment of vascular dementia","volume":"3","author":"Zhao","year":"2011","journal-title":"Med J West China"},{"key":"R26-20230914","first-page":"12","article-title":"Effects of atorvastatin on cognitive function and blood lipids in patients with vascular cognitive impairment at different stages","author":"Gu","year":"2010","journal-title":"Chin J Geriatr Heart Brain Vessel Dis"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","article-title":"A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease","volume":"77","author":"Sano","year":"2011","journal-title":"Neurology"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ana.10292","article-title":"Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial","volume":"52","author":"Simons","year":"2002","journal-title":"Ann Neurol"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1600-0404.2006.00689.x","article-title":"Statin therapy in Alzheimer's disease","volume":"185","author":"Sparks","year":"2006","journal-title":"Acta Neurol Scand Suppl"},{"key":"R30-20230914","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.54.11.2061","article-title":"Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study","volume":"54","author":"Wang","year":"2000","journal-title":"Neurology"},{"key":"R31-20230914","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1517\/14656566.2014.902446","article-title":"Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan","volume":"15","author":"Nakamura","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"R32-20230914","first-page":"23","article-title":"To observe the clinical effect of memantine hydrochloride in the treatment with dementia caused by Parkinson","author":"Shan","year":"2017","journal-title":"Chin J Clin Ration Drug Use"},{"key":"R33-20230914","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer's disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N Engl J Med"},{"key":"R34-20230914","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1353-8292(99)00017-9","article-title":"The geography of fundholding in southwest England: implications for the evolution of primary care groups","volume":"5","author":"Asthana","year":"1999","journal-title":"Health Place"},{"key":"R35-20230914","first-page":"89","article-title":"EFNS guidelines for the diagnosis and management of Alzheimer's disease","author":"Horta","year":"2011","journal-title":"Chin J Geriatr"},{"key":"R36-20230914","article-title":"EFNS guidelines for the diagnosis and management of Alzeheimer disease","author":"Hort","year":"2010","journal-title":"Chin J Geriatr"},{"key":"R37-20230914","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3233\/JAD-150437","article-title":"Lithium as a treatment for Alzheimer's disease: a systematic review and meta-analysis","volume":"48","author":"Matsunaga","year":"2015","journal-title":"J Alzheimer's Dis"},{"key":"R38-20230914","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamaneurol.2016.3783","article-title":"Sex and race differences in the association between statin use and the incidence of Alzheimer Disease","volume":"74","author":"Zissimopoulos","year":"2017","journal-title":"JAMA Neurol"},{"key":"R39-20230914","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1161\/hs1201.099663","article-title":"Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease","volume":"32","author":"Sterzer","year":"2001","journal-title":"Stroke"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201907050-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T22:03:03Z","timestamp":1694728983000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201907050-00022"}},"subtitle":["A network meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":39,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000016091","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}